Relapsed and refractory acute myeloid leukemia
Conditions
Interventions
Group 1 :Infusion DNT
Sponsors
The First Affiliated Hospital of School of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Understand and voluntarily sign the informed consent; 2. Age: 18-75 years old; 3. According to the 2016 WHO diagnostic criteria for AML, patients diagnosed as AML other than acute promyelocytic, who have achieved complete remission after 2 courses of regular treatment or have achieved complete remission after previous treatment, but the latest assessment suggests disease recurrence.
Exclusion criteria
Exclusion criteria: 1. Patients diagnosed with acute promyelocytic leukemia; 2. It is known that there is persistent infection within 3 days and needs to receive systemic treatment; 3. Subjects known to have active central nervous system leukemia; 4. Within the first 3 days of infusion of DNT cells, the subject was treated with Cox2 inhibitors and glucocorticoids; 5. Patients who are allergic to immunotherapy or related drugs; 6. Patients with heart disease >= 2 NYHA grade or high blood pressure that is difficult to control and need treatment; 7. Patients who have previously received organ transplants or are about to receive organ transplants (except bone marrow or hematopoietic stem cell transplants); 8. Patients who have been judged by the investigator to be unsuitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| safety;Disease free survival;Relapse free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactCai Zhen
The First Affiliated Hospital of School of Medicine, Zhejiang University
Outcome results
None listed